Nuveen
ELTX icon

Nuveen’s Elicio Therapeutics ELTX Stock Holding History

Nuveen’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$82.1K Buy
45,121
+27,233
+152% +$75.6K ﹤0.01% 4067
2026
Q2 		$69.9K Buy
+17,888
New +$180K ﹤0.01% 3717
2022
Q2 		– Sell
-3,214
Closed -$69K – 3318
2022
Q1 		$69K Hold
3,214
– – ﹤0.01% 3262
2021
Q4 		$75K Hold
3,214
– – ﹤0.01% 3295
2021
Q3 		$338K Buy
+3,214
New +$347K ﹤0.01% 3236

Other funds holding ELTX

Shah Capital Management
Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
Leonteq Securities AG
Leonteq Securities AG Zurich, Switzerland $2.44B AUM 50.17% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Meyer Handelman Company
Meyer Handelman Company Rye Brook, New York $3.49B AUM 26.82% 1-Year Est. Return

Nuveen's ELTX Position: Q3 2026 in Review

Nuveen increased its Elicio Therapeutics (ELTX) stake by 152% in Q3 2026, buying an estimated $75.6K and bringing the position to 45,121 shares worth $82.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4067.

Nuveen first reported a position in ELTX in Q3 2021 and has held it in 5 quarters since. The position peaked at $338K in Q3 2021. 36 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

  • Nuveen held 45,121 shares of Elicio Therapeutics worth $82.1K as of Q3 2026.
  • Nuveen bought 27,233 Elicio Therapeutics shares in Q3 2026, an estimated $75.6K.
  • Elicio Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #4067 holding.
  • Nuveen first reported a position in Elicio Therapeutics in Q3 2021 and has held it in 5 quarters since.
  • Nuveen's Elicio Therapeutics position peaked at $338K in Q3 2021.
  • 36 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.